WILSON JAMES N sold $1.1M of CORT (indirect holdings)

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $110.69 ($110.27–$111.70, $1.11M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WILSON JAMES N
Published Sep 16, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale provides a data point for investors monitoring insider activity.

02

Market read

Insider sale of $1.1M by a director is a modest negative signal but unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the sale impact.

Relevance 5/10Novelty 5/10Timing: post‑market 2026‑09‑15

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Director Wilson James sold 10,000 shares for $1.1M via a 10b5-1 plan on 2026-09-15.

Expected impact

Slight short-term dip expected, limited to a few basis points.

Evidence & confidence

Insider sale by a director signals possible concerns, but size relative to float is modest.

Market effects

Minimal impact on the biotech sector; typical insider sale.

None beyond the company's own stock.

Not applicable.

Counterpoint

The sale may be routine liquidity planning; price could hold or rise on fundamentals.

Key entities

  • Corcept Therapeutics Inc.

    Biopharmaceutical company developing cortisol‑receptor antagonists.

  • Wilson James N.

    Director of Corcept Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.